PROCEPT BioRobotics (PRCT) – Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for PROCEPT BioRobotics (NASDAQ: PRCT):

• 3/6/2026 – PROCEPT BioRobotics is now covered by Robert W. Baird. They set a “neutral” rating and a $30.00 price target on the stock.
• 3/5/2026 – PROCEPT BioRobotics was upgraded by Robert W. Baird to “hold”.
• 2/28/2026 – PROCEPT BioRobotics was downgraded by Wall Street Zen from “hold” to “sell”.
• 2/27/2026 – PROCEPT BioRobotics had its price target lowered by Truist Financial Corporation from $47.00 to $30.00. They now have a “buy” rating on the stock.
• 2/26/2026 – PROCEPT BioRobotics had its price target lowered by Wells Fargo & Company from $51.00 to $34.00. They now have an “overweight” rating on the stock.
• 2/26/2026 – PROCEPT BioRobotics was downgraded by Jefferies Financial Group Inc. from “strong-buy” to “hold”.
• 2/26/2026 – PROCEPT BioRobotics had its price target lowered by Leerink Partners from $55.00 to $30.00. They now have an “outperform” rating on the stock.
• 2/26/2026 – PROCEPT BioRobotics had its price target lowered by TD Cowen from $50.00 to $34.00. They now have a “buy” rating on the stock.
• 2/26/2026 – PROCEPT BioRobotics had its price target lowered by Piper Sandler from $50.00 to $28.00. They now have an “overweight” rating on the stock.
• 2/26/2026 – PROCEPT BioRobotics had its “market perform” rating reaffirmed by Oppenheimer Holdings, Inc..
• 2/26/2026 – PROCEPT BioRobotics was downgraded by Bank of America Corporation from “neutral” to “underperform”. They now have a $20.00 price target on the stock, down from $38.00.
• 1/22/2026 – PROCEPT BioRobotics had its “sell (e+)” rating reaffirmed by Weiss Ratings.

Insider Activity at PROCEPT BioRobotics

In related news, EVP Kevin Waters sold 6,721 shares of the firm’s stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $23.70, for a total transaction of $159,287.70. Following the completion of the transaction, the executive vice president directly owned 152,264 shares in the company, valued at $3,608,656.80. This trade represents a 4.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Antal Rohit Desai bought 167,246 shares of the company’s stock in a transaction on Thursday, March 5th. The stock was purchased at an average cost of $25.58 per share, with a total value of $4,278,152.68. Following the completion of the transaction, the director owned 167,246 shares in the company, valued at $4,278,152.68. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders bought 426,262 shares of company stock worth $10,483,091 and sold 16,856 shares worth $405,811. 17.40% of the stock is currently owned by company insiders.

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.